← board
ABVX
distress 2/10 · well-funded / low risk$127.82-1%today-12% from 52w high
Revenue
pre-revenue
Liquidity
$492M
Runway
3.0 yrs
Shares 1y
0%
Price & events
+3.4% over 6M
CatalystRating changeDilutionFinancingdashed = today
-1.5%
1D
-7.2%
1W
+29.9%
1M
+13.1%
3M
+4.7%
6M
+86.3%
1Y
+961.6%
2Y
—
5Y
+1440.0%
All
Overview
- Market Cap
- $10.04B
- Enterprise Value
- $9.58B
- Volume
- 101.11K
- 52 Week Range
- $8.27 – $145
- Total Shares
- 78.54M
- Float Shares
- 67.11M
- Short %
- 5.49%
- % Held by Insiders
- 0.00%
- % Held by Institutions
- 70.62%
- RVOL
- 0.05x
- Beta
- -0.21
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Catalyst news & presentations · 1
- 2026-09-21earningsEarningsEarnings releaseyahoo
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $161 (+26% upside) · 11 analysts
- 2026-07-09Piper SandlerOverweight
- 2026-07-02Truist SecuritiesBuy
- 2026-07-01CitizensMarket Outperform
- 2026-06-30WedbushNeutral
- 2026-06-30Leerink PartnersOutperform
- 2026-06-30JefferiesHold → Buy
Competitors
- none identified
Recent news
- none
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.